KRAS and endometrial cancer: Therefore, in order to effectively investigate the effects of the Pten and K-ras signaling pathways in endometrial cancer, mice with uterine Pten ablation (PRcre/+Pten f/f; Pten d/d) and oncogenic K-ras mutation (K-rasG12D) were generated and mated to generate double mutant mice (PRcre/+Ptenf/fK-rasG12D; Ptend/dK-rasG12D) [23–25].